Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Completed

Conditions studied: Relapsing Forms of Multiple Sclerosis

In brief

The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.

Key facts

Study ID
NCT01903291
Run by
Biogen
People needed
333
Starts
2013-08-01
Expected to finish
2016-02-01
Last updated by the study team
2016-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.